OS RISCOS DA SEMAGLUTIDA PARA PERDA DE PESO
OS RISCOS DA SEMAGLUTIDA PARA PERDA DE PESO
-
DOI: 10.22533/at.ed.1052317111
-
Palavras-chave: Ozempic. Análago GLP-1. Obesidade.
-
Keywords: Ozempic, GLP-1 analogue, Obesity.
-
Abstract: Obesity is a disease treated as a global pandemic, which can have serious consequences, and it is important that it is correctly treatment. Drugs analogous to GLP-1 can make a great contribution to the treatment of obesity. Semaglutide is a medication that is part of this class of medications. The objective of this work was to carry out a literature review on the risks of semaglutide as a treatment for weight loss. Literature searches on the topic were carried out in the main electronic databases. Studies show the effectiveness of semaglutide for weight loss, showing a reduction in other diseases and risks associated with obesity. However, the studies also show that the use of semaglutide has adverse effects, mainly gastrointestinal, and that more studies are needed to indicate the safety of semaglutide in adverse events in the gallbladder, neoplasms and others.
- Cíntia da Silva dos Santos
- Luíza Danielle Canedo dos Santos
- Rita das Graças da Silva
- Anna Maly de Leão e Neves Eduardo
- ANNA MALY DE LEÃO E NEVES EDUARDO
- Axell Donelli Leopoldino Lima
- Ikaro Alves de Andrade
